# Final Quantitative Recommendation & Performance Target Assessment

## 1. Assessment of the 30% Compounded Monthly Return Target
- **Target Status:** **NOT ACHIEVED.**
- **Empirical Monthly Return Distribution for Best Strategy (`Exp1_Trend_Donchian_4H_Daily`):**
  - **Average Monthly Return:** -0.01%
  - **Median Monthly Return:** 0.0%
  - **Monthly Standard Deviation:** 2.64%
  - **Profitable Months:** 23.91%
  - **Best Month:** 8.84%
  - **Worst Month:** -4.13%
  - **Max Consecutive Losing Months:** 6
  - **Rolling 3-Month Average Return:** 0.06%
  - **Rolling 6-Month Average Return:** 0.28%
  - **Exact Shortfall to 30% Target:** **3000.0 basis points** per month.

### Quantitative Rationale:
A target of 30% net compounded monthly return corresponds to an annualized return exceeding **2,200% CAGR**. In perpetual futures trading with realistic taker fees (10 bps round-trip), slippage (6 bps round-trip), and 8-hour funding settlements, achieving 30% monthly compounded returns without catastrophic ruin is mathematically infeasible under strict risk constraints (3x leverage cap, 2.5% risk budget per trade). Strategies claiming 30% monthly consistently either overfit small in-sample slices, use reckless unconstrained leverage (>20x), or conceal drawdowns by omitting intra-bar mark-to-market excursions.

## 2. Final Strategy Shortlist & Acceptance Verdict
- **Best Identified Strategy:** `Exp1_Trend_Donchian_4H_Daily` (Multi-Timeframe 4H Donchian Breakout + 1D EMA Trend Filter + 72h Swing Horizon).
- **Secondary Candidate:** `Phase4_Combo_Regime_Selector` (Causal Regime Gated Selector).
- **Acceptance Status:** **NO VALIDATED EDGE APPROVED FOR LIVE EXECUTION.**
- **Rationale:**
  1. While `Exp1_Trend_Donchian_4H_Daily` dramatically outperforms the previous 1H baseline by capturing larger swing trends, the **95% moving block bootstrap confidence interval for trade expectancy is `[-117.51, 106.81]` bps**. Because the lower bound crosses below zero, positive expectancy is not established at the 95% confidence level.
  2. Under multiple-testing adjustment ($K=32$ trials evaluated), the **Deflated Sharpe Ratio (DSR) is 0.0**, failing to reject the null hypothesis of selection bias.
  3. Under Adverse Transaction Costs (7 bps fee, 5 bps slippage), strategy net expectancy degrades by ~16 bps.

## 3. Engineering Invariants
- Trading remains disabled:
  - `TRADING_ENABLED=False`
  - `MOCK_TRADING=True`
  - `PRODUCTION_READY=False`
  - `USE_BINANCE_TESTNET=True`
- No checkpoint promotion or live orders executed.
